Article
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2018
Eroglu Zeynep, Chen Y Ann, Gibney Geoffrey T, Weber Jeffrey S, Kudchadkar Ragini R, Khushalani Nikhil I, Markowitz Joseph, Brohl Andrew S, Tetteh Leticia F, Ramadan Howida, Arnone Gina, Li Jiannong, Zhao Xiuhua, Sharma Ritin, Darville Lancia N F, Fang Bin, Smalley Inna, Messina Jane L, Koomen John M, Sondak Vernon K, Smalley Keiran S M
Abstract excerpt
Purpose: BRAF inhibitors are clinically active in patients with advanced BRAFV600-mutant melanoma, although acquired resistance remains common. Preclinical studies demonstrated that resistance could be overcome using concurrent treatment with the HSP90 inhibitor XL888.Patients and Methods: Vemurafenib (960 mg p.o. b.i.d.) combined with escalating doses of XL888 (30, 45, 90, or 135 mg p.o. twice weekly) was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.